Search

Your search keyword '"Hillmann P"' showing total 363 results

Search Constraints

Start Over You searched for: Author "Hillmann P" Remove constraint Author: "Hillmann P" Database Supplemental Index Remove constraint Database: Supplemental Index
363 results on '"Hillmann P"'

Search Results

1. Swamp Reforestation in Coastal Louisiana, USA Exposes Landscape Scale Differences in Survival and Growth Across Two Hydrologically Restored Regions

2. Games als Türöffner für kulturelle Bildung: Förderung digitaler Spielekultur im ländlichen Raum.

8. Effect of Ointments of Sulphur or Pyrogenium on Larvae of Cochliomyia hominivorax (Diptera: Calliphoridae).

9. Stressful life events across the lifespan and inflammation: An integrative data analysis

11. Becoming glocal bureaucrats: mayors, institutions and civil society in smaller cities in Brandenburg during the ‘migration crisis’, 2015–17

12. Retinal blood flow imaging with combined full-field swept-source optical coherence tomography and laser Doppler holography

16. 4‑(Difluoromethyl)-5-(4-((3R,5S)‑3,5-dimethylmorpholino)-6-((R)‑3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders.

18. Structure and concept of ICU rounds: the VIS-ITS survey

21. 4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders

22. Simultaneous functional imaging of neuronal and photoreceptor layers in living human retina

25. Wind, waves, tides, and human error? – Influences on litter abundance and composition on German North Sea coastlines: An exploratory analysis.

26. (S)‑4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.

27. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

28. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

29. Sow serenity: automatic long-term measurement of lying behavior in crates and free-farrowing pens using 3D accelerometers

32. Discovery and Preclinical Characterization of 5‑[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.

34. Effect of supplementation of pelleted hazel (Corylus avellana) leaves on blood antioxidant activity, cellular immune response, and heart beat parameters in sheep1.

35. A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

36. Zwischen Realitätsverweigerung und Pragmatismus: Migration-led regeneration in Genua und Manchester

37. Computational adaptive optics for optical coherence tomography using multiple randomized subaperture correlations

39. (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase

40. Biphasic Formation of 2D Nanomembranes by Photopolymerization of Diacetylene Lipids as Revealed by Infrared Difference Spectroscopy

41. Artifacts in speckle tracking and multi-aperture Doppler OCT imaging of lateral motion

42. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.

43. Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders

44. Knochenzysten – Differenzialdiagnose und therapeutisches Vorgehen

46. Enhanced Anticancer Efficacy by Drug Chemotherapy and Cold Atmospheric Plasma Against Melanoma and Glioblastoma Cell Lines In Vitro

47. Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients

49. Stable Engraftment of Bifidobacterium longum AH1206 in the Human Gut Depends on Individualized Features of the Resident Microbiome.

Catalog

Books, media, physical & digital resources